Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Buys 5,000 Shares of Company Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 5,000 shares of the business’s stock in a transaction dated Friday, October 30th. The stock was purchased at an average cost of $3.17 per share, with a total value of $15,850.00. Following the transaction, the chief executive officer owned 685,000 shares of the company’s stock, valued at approximately $2,171,450. The trade was a 0.74% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Thursday, October 22nd, Amit Kumar acquired 8,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $2.72 per share, with a total value of $21,760.00.
• On Thursday, September 24th, Amit Kumar acquired 7,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.78 per share, for a total transaction of $19,460.00.
• On Thursday, September 10th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $2.75 per share, for a total transaction of $8,250.00.
• On Thursday, September 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $2.76 per share, for a total transaction of $13,800.00.

Anixa Biosciences Stock Down 4.2%

Shares of ANIX opened at $2.99 on Tuesday. The firm has a 50-day moving average price of $2.96 and a 200 day moving average price of $2.97. The firm has a market capitalization of $103.94 million, a PE ratio of -9.34 and a beta of 0.47. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). On average, equities analysts expect that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors have recently added to or reduced their stakes in ANIX. Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Anixa Biosciences in the second quarter valued at $29,000. Integrated Wealth Concepts LLC bought a new position in Anixa Biosciences in the second quarter worth $30,000. Simplicity Wealth LLC bought a new position in Anixa Biosciences in the second quarter worth $34,000. Finally, NewEdge Wealth LLC acquired a new stake in Anixa Biosciences during the second quarter worth $35,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on ANIX shares. Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen lowered shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. HC Wainwright decreased their target price on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Finally, Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.00.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.